Artigo
Functionalized-radiolabeled hydroxyapatite/tenorite nanoparticles as theranostic agents for osteosarcoma
Carregando...
Notas
Data
Orientadores
Editores
Coorientadores
Membros de banca
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier
Faculdade, Instituto ou Escola
Departamento
Programa de Pós-Graduação
Agência de fomento
Tipo de impacto
Áreas Temáticas da Extenção
Objetivos de Desenvolvimento Sustentável
Dados abertos
Resumo
Abstract
Hydroxyapatite (HA) nanoparticles (NPs) doped with different radioisotopes for use as theranostic systems play an important role in scientific research nowadays due to their ability to simultaneously act in the treatment and diagnosis of various types of cancers. In this work, we describe the synthesis and characterization of a hydroxyapatite/tenorite nanocomposite functionalized with folic acid, representing a nanotheranostic material with potential for application as an agent in positron emission tomography imaging systems and to act specifically in the treatment and diagnosis of osteosarcoma. 64Cu and 32P were produced by nuclear activation in the TRIGA reactor at CDTN. The obtained samples were characterized by XRD with Rietveld refinement, XAFS, SEM, BET, TGA, FTIR, CHN, ICP-AES, XPS and gamma spectroscopy. We investigated how CuO grows in HA NPs, the stability of the interactions between CuO and HA constituents and the interactions between folic acid and the surface of the HA NPs. The results indicate the formation of a second phase (tenorite) besides hydroxyapatite, and that the interactions between the two phases are stable, resulting in a nanocomposite. Furthermore, the activation of 64Cu and 32P inside the HA matrix, through the exposition to a neutron flux, produces a theranostic material of interest for biological tests.
Descrição
Área de concentração
Agência de desenvolvimento
Palavra chave
Marca
Objetivo
Procedência
Impacto da pesquisa
Resumen
ISBN
DOI
Citação
CIPRESTE, M. F. et al. Functionalized-radiolabeled hydroxyapatite/tenorite nanoparticles as theranostic agents for osteosarcoma. Ceramics International, [S.l.], v. 44, n. 15, p. 17800-17811, Oct. 2018.
